Efficacy and Safety of Prasugrel by Stroke Subtype: A Sub-Analysis of the PRASTRO-I Randomized Controlled Trial

Aims: The efficacy of antiplatelet therapy may vary among different disease subtypes. Prasugrel is generally a more potent, consistent, and fast-acting platelet inhibitor than clopidogrel. This sub-analysis of the phase III comparison of PRAsugrel and clopidogrel in Japanese patients with ischemic S...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitazono, Takanari, Toyoda, Kazunori, Kitagawa, Kazuo, Nagao, Takehiko, Yamagami, Hiroshi, Uchiyama, Shinichiro, Tanahashi, Norio, Matsumoto, Masayasu, Minematsu, Kazuo, Nagata, Izumi, Nishikawa, Masakatsu, Nanto, Shinsuke, Ikeda, Yasuo, Shirai, Toshiaki, Abe, Kenji, Ogawa, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957026/
https://www.ncbi.nlm.nih.gov/pubmed/32493881
http://dx.doi.org/10.5551/jat.56093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957026/
https://www.ncbi.nlm.nih.gov/pubmed/32493881
http://dx.doi.org/10.5551/jat.56093

Ejemplares similares